Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 511

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia

Open access
Laviolette, Michel, Gossage, David L., Gauvreau, Gail, Leigh, Richard, Olivenstein, Ron, Katial, Rohit, Busse, William W., Wenzel, Sally, Wu, Yanping, Datta, Vivekananda, Kolbeck, Roland, Molfino, Nestor A.·2013·Journal of Allergy and Clinical Immunology

Abstract

Background Many subjects with asthma exhibit sputum eosinophilia associated with exacerbations. Benralizumab targets eosinophils by binding interleukin-5 receptor alpha, inducing apoptosis via antibody-dependent cell-mediated cytotoxicity. Objectives To evaluate the safety of benralizumab in adults with eosinophilic asthma, and its effects on eosinophil counts in airway mucosal/submucosal biopsies, sputum, bone marrow, and peripheral blood. Methods In this multicenter, double-blind, placebo-controlled Phase I study, 13 subjects were randomized to single intravenous placebo or benralizumab 1 mg/kg (day 0) [Cohort 1], and 14 subjects were randomized to three monthly subcutaneous doses of placebo or benralizumab 100 or 200 mg (days 0, 28, and 56) [Cohort 2]. Cohorts 1 and 2 were consecutive. Results The incidence of adverse events was similar between groups. No serious adverse events related to benralizumab occurred. Cohort 1: intravenous benralizumab produced a median decrease from baseline of 61.9% in airway mucosal eosinophils (day 28; placebo: +19.6%; P = .28), 18.7% (day 21) in sputum and 100% (day 28) in blood. Eosinophils were not detectable in bone marrow of benralizumab-treated subjects (day 28, n=4). Cohort 2: subcutaneous benralizumab demonstrated a combined (100 + 200 mg) median reduction of 95.8% in airway eosinophils (day 84; placebo −46.7%; P = .06), 89.9% (day 28) in sputum and 100% (day 84) in blood. Conclusion Single-dose intravenous and multiple-dose subcutaneous benralizumab reduced eosinophil counts in airway mucosa/submucosa and sputum, and suppressed eosinophils in bone marrow and peripheral blood. The safety profile supports further development. Additional studies are needed to assess clinical benefit in asthma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaci.2013.05.020

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 511

Metadata

Authors
Laviolette, M., Gossage, D. L., Gauvreau, G., Leigh, R., Olivenstein, R., Katial, R., Busse, W. W., Wenzel, S., Wu, Y., Datta, V., Kolbeck, R., & Molfino, N. A.
Venue
Journal of Allergy and Clinical Immunology
Publisher
Elsevier BV
Published
2013-11
Volume
132
Issue
5
Pages
1086-1096.e5
ISSN
0091-6749 (ISSN-L)
OpenAlex
W2065797637
Cited by
511
References
25
FWCI
25.30
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. https://app.cochat.ai/papers/10.1016/j.jaci.2013.05.020
The paper
Laviolette, M., Gossage, D. L., Gauvreau, G., Leigh, R., Olivenstein, R., Katial, R., Busse, W. W., Wenzel, S., Wu, Y., Datta, V., Kolbeck, R., & Molfino, N. A. (2013). Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2013.05.020

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.